BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 17536171)

  • 1. Heat shock protein 90: the cancer chaperone.
    Neckers L
    J Biosci; 2007 Apr; 32(3):517-30. PubMed ID: 17536171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat shock protein 90.
    Neckers L; Ivy SP
    Curr Opin Oncol; 2003 Nov; 15(6):419-24. PubMed ID: 14624223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chaperoning oncogenes: Hsp90 as a target of geldanamycin.
    Neckers L
    Handb Exp Pharmacol; 2006; (172):259-77. PubMed ID: 16610363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp90 inhibitors as novel cancer chemotherapeutic agents.
    Neckers L
    Trends Mol Med; 2002; 8(4 Suppl):S55-61. PubMed ID: 11927289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis.
    Tsutsumi S; Neckers L
    Cancer Sci; 2007 Oct; 98(10):1536-9. PubMed ID: 17645779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.
    Neckers L
    Curr Top Med Chem; 2006; 6(11):1163-71. PubMed ID: 16842153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents.
    Neckers L; Neckers K
    Expert Opin Emerg Drugs; 2002 Oct; 7(2):277-88. PubMed ID: 15989551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
    Neckers L
    Curr Med Chem; 2003 May; 10(9):733-9. PubMed ID: 12678776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat shock protein 90: a unique chemotherapeutic target.
    Cullinan SB; Whitesell L
    Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?
    Isaacs JS
    Expert Opin Investig Drugs; 2005 Jun; 14(6):569-89. PubMed ID: 16004589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
    Garg G; Khandelwal A; Blagg BS
    Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.
    Brandt GE; Blagg BS
    Curr Top Med Chem; 2009; 9(15):1447-61. PubMed ID: 19860731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
    Miyata Y
    Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update.
    Neckers L; Neckers K
    Expert Opin Emerg Drugs; 2005 Feb; 10(1):137-49. PubMed ID: 15757409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSP90 and its inhibitors.
    Hao H; Naomoto Y; Bao X; Watanabe N; Sakurama K; Noma K; Motoki T; Tomono Y; Fukazawa T; Shirakawa Y; Yamatsuji T; Matsuoka J; Takaoka M
    Oncol Rep; 2010 Jun; 23(6):1483-92. PubMed ID: 20428801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
    Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
    Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer.
    Haque A; Alam Q; Alam MZ; Azhar EI; Sait KH; Anfinan N; Mushtaq G; Kamal MA; Rasool M
    Curr Pharm Des; 2016; 22(20):2947-59. PubMed ID: 27013225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for stalling malignancy: targeting cancer's addiction to Hsp90.
    Prodromou C
    Curr Top Med Chem; 2009; 9(15):1352-68. PubMed ID: 19860736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
    Donnelly A; Blagg BS
    Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.